Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGT-53 with Topotecan and Cyclophosphamide in Pediatric Refractory or Recurrent Solid Tumors
NCT02354547Phase 1Suspended
- Sponsor
- SynerGene Therapeutics, Inc.
- Start
- Dec 2014
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGT-53 in solid tumor, sponsored by SynerGene Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicities and Recommended Phase 2 Dose. Started Dec 2014; status: suspended.
02
Drugs
SGT-53
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02354547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354547.